If You Invested $1,000 in Design Therapeutics, Inc. (DSGN)
This article examines the historical performance of investing $1,000 in Design Therapeutics, Inc. (DSGN) over various periods, showing substantial gains in the last year but losses over longer terms. It also provides a detailed overview of the company, a clinical-stage biotechnology firm, its GeneTAC® platform, lead clinical programs for Friedreich ataxia and Fuchs endothelial corneal dystrophy, and its expansion into myotonic dystrophy type-1 and Huntington’s disease. DSGN focuses on developing treatments for serious degenerative genetic diseases by modulating gene expression.
Price to sales forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This article displays the "Price to sales forward" financial metric for Design Therapeutics, Inc. (NASDAQ: DSGN). The content includes the company's stock symbol, market, and a brief mention of the financial data period, value, and change.
Price to earnings forward of Design Therapeutics, Inc. – NASDAQ:DSGN
This page from TradingView displays financial information for Design Therapeutics, Inc. (NASDAQ: DSGN), specifically focusing on its forward price-to-earnings ratio. The content indicates that the market was closed at the time of access, with no trades occurring. The page also lists various data providers, copyright information, and links to other TradingView features and resources.
Design Therapeutics (Nasdaq:DSGN) - Stock Analysis
This article provides a stock analysis of Design Therapeutics (DSGN), highlighting its current market performance, risk factors, and pipeline developments. The company, a clinical-stage biopharmaceutical firm focusing on genetic diseases, shows significant stock growth over the past year but faces financial challenges with unprofitability and forecasted earnings decline. Key developments include clinical trials for Myotonic Dystrophy Type-1 and Friedreich Ataxia, with both positive biomarker data and new risk assessments impacting investor outlook.
Design Therapeutics begins dosing DM1 drug in phase 1 trial By Investing.com
Design Therapeutics (NASDAQ:DSGN) has initiated patient dosing for its DT-818 drug in a Phase 1 clinical trial for adults with myotonic dystrophy type-1, leading to a 6.7% surge in its stock. The company anticipates reporting data from this trial in 2027 and continues to advance other GeneTAC platform-based therapies for various diseases. Despite trading above its Fair Value, the company maintains a strong financial position, recently surpassing Q1 2026 earnings per share forecasts and showing positive data in another clinical trial for Friedreich ataxia, leading RBC Capital to raise its price target.
Design Therapeutics begins DM1 trial for DT-818, aims at genetic cause
Design Therapeutics (Nasdaq: DSGN) has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC small molecule, for adults with myotonic dystrophy type-1 (DM1). DT-818 is designed to address the underlying genetic cause of DM1 by selectively reducing the transcription of the mutant DMPK allele. Data from this open-label study, which will assess safety, tolerability, pharmacokinetics, and pharmacodynamics, is anticipated in 2027.
Design Therapeutics stock rises on Phase 1 trial dosing start By Investing.com
Design Therapeutics Inc. (NASDAQ:DSGN) shares rose in premarket trading after the company announced the initiation of patient dosing in its Phase 1 trial for DT-818. This GeneTAC small molecule aims to treat myotonic dystrophy type-1 (DM1) by targeting the underlying genetic cause of the disease. The company expects to report data from this safety and tolerability study in 2027.
Design Therapeutics begins dosing DM1 drug in phase 1 trial
Design Therapeutics (NASDAQ:DSGN) has commenced patient dosing in a Phase 1 clinical trial for DT-818, a potential treatment for myotonic dystrophy type-1 (DM1). The company's stock surged on the news, having already seen significant gains over the past year. DT-818 is designed to reduce the mutant DMPK allele associated with the progressive neuromuscular disease, and Design Therapeutics expects to release trial data in 2027.
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has initiated patient dosing for its Phase 1 multiple-ascending dose (MAD) clinical trial of DT-818, a GeneTAC® small molecule for Myotonic Dystrophy Type-1 (DM1). DT-818 is designed to address the genetic cause of DM1 by selectively reducing the transcription of the mutant DMPK allele. The company anticipates reporting data from this study in 2027.
Design Therapeutics spikes as RBC upgrades on an eventful 2026
Design Therapeutics (NASDAQ:DSGN) saw its shares rise after RBC Capital upgraded the stock, citing upcoming catalysts and a potentially "eventful" 2026. The upgrade reflects optimism about the company's future prospects and clinical developments.
Design Therapeutics spikes as RBC upgrades on an eventful 2026
Design Therapeutics (DSGN) shares surged after RBC Capital Markets upgraded the stock. The upgrade was based on expectations for an "eventful 2026," particularly regarding the company's DM1 program, which RBC now believes has a higher likelihood of success.
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to Russell Small Cap Comp Growth Benchmark
Design Therapeutics, Inc. (DSGN) has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion is among several recent updates for the company within the Russell indices, including additions to the Russell 2500 Growth Benchmark and Russell Microcap Growth Benchmark, and exclusions from the Russell 2000 Value Benchmark and Russell Microcap Value Benchmark Index. The biotech company is focused on developing GeneTACT molecules for diseases caused by inherited nucleotide repeat expansion mutations, with therapies in clinical trials for Friedreich ataxia and Fuchs Endothelial Corneal Dystrophy (FECD).
Design Therapeutics, Inc.(NasdaqGS: DSGN) dropped from Russell 2000 Value Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been removed from the Russell 2000 Value Benchmark, as announced on June 29, 2026. This news comes alongside several other Russell index adjustments for the company, including being added to the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell Microcap Growth, and Russell 2000 Growth benchmarks, while also being dropped from the Russell Microcap Value Index. The biotechnology company focuses on developing GeneTACT molecules for diseases caused by inherited nucleotide repeat expansion mutations.
Design Therapeutics, Inc.(NasdaqGS: DSGN) added to Russell 3000E Growth Benchmark
Design Therapeutics, Inc. (NasdaqGS: DSGN) has been added to the Russell 3000E Growth Benchmark. The company specializes in developing GeneTACT molecules—small-molecule gene-targeted chimera therapeutic candidates designed for diseases caused by inherited nucleotide repeat expansion mutations. Design Therapeutics is currently advancing programs for Friedreich ataxia and Fuchs Endothelial Corneal Dystrophy, with both DT-216P2 and DT-168 in clinical trials.
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
Design Therapeutics (NASDAQ:DSGN), a loss-making company, saw its share price soar by 274% over the last year. Despite an increase in cash burn to US$54 million, the company maintains a robust cash runway of 4.1 years based on its US$223 million cash reserves. Analysts believe Design Therapeutics could easily raise additional capital if needed, given its cash burn represents only 6.5% of its market capitalization.
Design Therapeutics, Inc. Actuals & Estimates (NASDAQ:DSGN)
This article provides an overview of Design Therapeutics, Inc. (DSGN) stock performance, financial estimates, and analyst forecasts. It includes details on the current stock price, volatility, market capitalization, historical highs and lows, and upcoming earnings reports, along with frequently asked questions about investing in DSGN.
DSGN Forecast — Price Target — Prediction for 2027
This article provides an outlook on Design Therapeutics, Inc. (DSGN) stock, including analyst price targets, historical performance, and financial data. Analysts predict a max estimate of $22.00 and a min estimate of $20.00 for DSGN. The company's stock has shown significant growth over the past year, with a 237.97% increase, and has a market capitalization of $839.42 million.
Design Therapeutics Inc (DSGN) Institutional Confidence
Design Therapeutics Inc (DSGN) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry, with institutional shareholding at 61.89%, a decrease of 8.26% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 2.61 million shares, representing 4.36% of shares outstanding.
Design Therapeutics Inc (DSGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Design Therapeutics Inc (DSGN), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. As of June 18, 2026, DSGN has a price momentum score of 9.66 and is showing a "Buy" signal based on its moving averages and other technical indicators, despite some indicators showing neutral or sell signals. The stock is currently trading between resistance at $13.46 and support at $10.65, suggesting suitability for range-bound swing trading.
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
Oppenheimer has reiterated its Buy rating for Design Therapeutics (DSGN.US), maintaining a target price of $21. This indicates continued analyst confidence in the company's prospects.
Design Therapeutics Inc (DSGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey attempts to provide a revenue breakdown for Design Therapeutics Inc (DSGN), covering its business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant data, leading the report to state that this information is currently unavailable. The page also includes current stock performance and general company information for DSGN.
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Design Therapeutics Inc (DSGN), highlighting its current earnings forecast score, average price target of $12.50, and analyst ratings. Based on 7 analysts, most support a "Buy" trend for the stock. The article also touches on past and future EPS expectations.
Design Therapeutics (DSGN) grants director David Shapiro 30,000 options
Design Therapeutics (DSGN) has granted director David Shapiro 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months starting from June 9, 2026, and will be fully vested by the company’s next annual meeting of stockholders. This compensation-related award was reported in an SEC Form 4 filing on June 11, 2026.
Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55
Design Therapeutics (DSGN) director George Simeon was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months after June 9, 2026, or fully by the company's next annual stockholder meeting. This transaction was reported in a Form 4 SEC filing, indicating a compensation-related award rather than an open-market purchase or sale.
Design Therapeutics (NASDAQ: DSGN) details outcomes of 2026 shareholder meeting votes
Design Therapeutics (NASDAQ: DSGN) has released the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected Simeon George, M.D. as a Class II director and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The report details the specific vote counts for each proposal, including votes for, votes withheld, and broker non-votes.
Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike
Design Therapeutics (DSGN) director Rodney W. Lappe was granted 30,000 stock options with an exercise price of $10.55 per share, expiring on June 8, 2036. The options will vest in equal monthly installments over 12 months following June 9, 2026, or fully by the company's next annual stockholder meeting. This transaction was reported as compensation in a Form 4 SEC filing.
[Form 4] Design Therapeutics, Inc. Insider Trading Activity
Design Therapeutics, Inc. director John P. Schmid was granted 30,000 stock options with an exercise price of $10.55 per share, expiring in 2036. These options will vest in equal monthly installments over 12 months starting June 9, 2026, or fully vest by the company's next annual meeting. Following this transaction, Schmid directly holds options for 30,000 shares of Design Therapeutics (DSGN).
Director at Design Therapeutics (DSGN) awarded 30,000 stock options
Design Therapeutics (DSGN) director Heather A. Berger was granted 30,000 stock options with an exercise price of $10.55 per share. These options will vest in equal monthly installments over 12 months following June 9, 2026, or fully vest by the company's next annual meeting of stockholders, aligning with her board service. The transaction is reported as neutral in impact and sentiment.
Director at Design Therapeutics (DSGN) awarded options on 30,000 shares
Design Therapeutics (DSGN) director Justin D. Gover has been granted stock options for 30,000 shares of common stock. These options have an exercise price of $10.55 per share and an expiration date of June 8, 2036. The shares will vest in equal monthly installments over 12 months starting June 9, 2026, or fully by the company's next annual meeting, whichever comes first.
Point72-affiliated holders report 5.1% stake in Design Therapeutics (DSGN)
Point72-affiliated entities, including Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen, have reported a passive 5.1% stake in Design Therapeutics (DSGN). This holding amounts to 3,197,764 shares of common stock as of June 8, 2026, with shared voting and dispositive power. The disclosure was made via a Schedule 13G filing, indicating an investment purpose rather than an intent to control the company.
DSGN: Early clinical data in Friedreich's ataxia support rapid advancement to registrational studies
Design Therapeutics, Inc. (DSGN) has reported positive early clinical data for its novel small molecule genomic medicine platform in treating Friedreich's ataxia. The data showed significant biomarker and clinical improvements at a 1 mg/kg dose, supporting the advancement of ongoing studies towards registrational development. A major update regarding these studies is anticipated in Q4.
DSGN Stock Chart | DESIGN THERAPEUTICS INC (NASDAQ:DSGN)
This page provides a stock chart for DESIGN THERAPEUTICS INC (NASDAQ:DSGN). It displays the company's current stock price, which closed at 10.44 USD with a slight decrease of 0.38%. The page also offers various tools and data for stock analysis, including daily, weekly, and monthly charts.
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN)
Design Therapeutics (DSGN) shares saw a significant jump following the announcement of encouraging early data from its Phase 1 clinical trial of DT-216 for Friedreich ataxia. The company reported that DT-216 showed dose-dependent increases in frataxin levels and was well-tolerated, suggesting potential as a treatment for this rare neurological disorder.
Piper Sandler Reaffirms Their Buy Rating on Design Therapeutics (DSGN)
Piper Sandler analyst Yasmeen Rahimi has reaffirmed a Buy rating on Design Therapeutics (DSGN) and set a price target of $20.00. Rahimi is a 5-star analyst with a strong track record. Design Therapeutics currently holds an analyst consensus of Strong Buy with a price target of $19.60, despite reporting a quarterly GAAP net loss of $17.64 million.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, a clinical-stage biotechnology company, announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The company is developing GeneTAC® small molecules for various degenerative genetic diseases, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. A live webcast of the event will be available on the company's investor relations website.
Biotech Design Therapeutics to join Jefferies 2026 healthcare fireside chat
Design Therapeutics (Nasdaq: DSGN) is scheduled to participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, at 1:25 p.m. ET in New York. A live webcast and 30-day archive will be available on the company's website. The announcement highlights an ongoing pattern of routine investor outreach by Design Therapeutics as it continues to advance its GeneTAC® gene targeted chimera small molecule programs for serious degenerative genetic diseases.
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Design Therapeutics, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, where management will hold a fireside chat on Thursday, June 4, 2026, at 1:25 p.m. ET. The company is a clinical-stage biotechnology firm focused on developing treatments for serious degenerative genetic diseases using its GeneTAC® platform. A live webcast of the event will be available on their website and archived for 30 days.
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
Piper Sandler has reiterated its Buy rating for Design Therapeutics (DSGN.US) and maintained a target price of $20. This indicates the firm's continued confidence in the company's stock performance.
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX)
Analysts are sharing conflicting opinions on several healthcare companies, including Design Therapeutics (DSGN), Pro Medicus Limited (PMCUF), and Boston Scientific (BSX). RBC Capital analysts maintained Buy ratings on Design Therapeutics and Boston Scientific, with price targets of $20.00 and $100.00 respectively, while maintaining a Hold rating on Pro Medicus Limited with a target of A$195.00. The consensus for all three stocks remains a Strong Buy with significant potential upside.
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22
Craig-Hallum has reiterated its Buy rating for Design Therapeutics (DSGN.US) and increased its price target for the company to $22. This update suggests a positive outlook from the analyst firm regarding the company's future stock performance and potential.
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20
RBC Capital has reiterated its "Buy" rating on Design Therapeutics (DSGN.US) and increased its price target for the stock to $20. This indicates a positive outlook from the investment firm regarding the company's future performance.
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia - Slideshow (NASDAQ:DSGN) 2026-05-19
Design Therapeutics, Inc. (DSGN) has released a slideshow discussing data from its RESTORE-FA Trial of DT-216P2, a drug candidate for Friedreich Ataxia. The company published this slide deck in conjunction with the event to provide details on the trial's findings. This report was generated by Seeking Alpha's transcripts team.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics announced positive biomarker and clinical findings from its Phase 1/2 RESTORE-FA trial for DT-216P2, a treatment for Friedreich ataxia. The therapy showed dose-dependent increases in frataxin levels and improved clinical measures, leading to an initial stock surge. However, the stock later fell despite the positive data, with shares down over 28% at publication time.
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia patients, showing dose-dependent improvements in clinical measures and increased frataxin levels, with the treatment being generally well-tolerated. The company plans to pursue a registrational path for DT-216P2 and is performing strongly in the market, holding more cash than debt and exceeding short-term obligations while analysts revise earnings estimates upward.
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia
Design Therapeutics announced positive biomarker and clinical data from its Phase 1/2 RESTORE-FA trial for DT-216P2 in Friedreich ataxia patients. The treatment showed improvements in the Friedreich’s Ataxia Rating Scale, Upright Stability Score, and patient-reported fatigue, alongside dose-dependent increases in frataxin. DT-216P2 was well-tolerated, and the company plans to pursue a registrational path, with an update expected in Q4 2026.
Design Therapeutics shares jump on encouraging Friedreich ataxia trial results (DSGN)
Design Therapeutics (DSGN) shares saw a significant increase following the announcement of encouraging interim results from its Phase 1 multiple-ascending dose clinical trial of DT-216 for Friedreich ataxia. The data showed dose-dependent increases in frataxin protein and improvements in disease relevant biomarkers, with DT-216 being well-tolerated. This positive news suggests potential for a new treatment option for the rare genetic disorder.
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics (DSGN) saw its stock surge then fall after releasing positive Phase 1/2 RESTORE-FA trial data for DT-216P2, a treatment for Friedreich ataxia. The drug showed dose-dependent increases in frataxin levels and significant clinical improvements, exceeding expectations for fatigue reduction. Despite the promising data and plans for a registrational path, the stock was down 28.88% at the time of publication.
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk
Design Therapeutics (NASDAQ: DSGN) is experiencing a significant stock decline, with shares down over 25% today. This puts the company on track for its largest percentage decrease since August 2023. This data indicates a notable negative movement in the company's stock performance.
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
Design Therapeutics announced positive early Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich ataxia patients, demonstrating meaningful functional and fatigue improvements, along with robust frataxin biomarker increases. The drug was generally well tolerated, and the company plans to pursue a registrational path with further updates expected in late 2026. Despite positive clinical news, Spark, TipRanks' AI Analyst, rates DSGN as Neutral due to weak financial performance outweighing positive technical momentum and pipeline progress.
Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia
Design Therapeutics (DSGN) has announced positive four-week IV data from its RESTORE-FA trial for DT-216P2. The results demonstrated both clinical improvements and comprehensive biomarker activity in patients with Friedreich Ataxia.
